Due to the rarity and heterogeneity of soft-tissue sarcoma, investigations into new treatments and methods of management have posed challenges. Although intensive chemotherapy and the establishment of surgical procedures have improved the outcomes of patients with soft-tissue sarcomas, there remains limited options for anticancer agents, a high incidence of postoperative complications, and an unsatisfactory curative rate for recurrent and metastatic soft-tissue sarcomas. This reprint contains original/review articles on molecular biology, the microenvironment, anticancer agents, and the management of soft-tissue sarcomas.
